Award Winners at the Fourth Edition of the Martín Villar Research Awards
Grifols is a company which is committed to encouraging scientific investigation; one of the ways is does this is through the Martín Villar Awards for research into hemostasis. At the fourth edition of the awards. the panel of judges, made up of specialists in this field, decided to make awards to the original contributions delivered by the following researchers:
- First prize: Bernd Engelmann for the research project Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases.
- This publication reports that neutrophil serine-proteases, in addition to having antimicrobial activity, activate blood coagulation. This is an important finding that may explain some pathogenic mechanisms contributing to the development of occlusive cardiovascular pathologies, such as myocardial infarction. These findings offer a rationale for the development of new drugs targeting disease-specific thrombotic complications.
- Second prize: Jonathan Finn for the research project Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.
- This work, using a canine inhibitor Hemophilia A model provides a new approach in the eradication of Hemophila A inhibitors. The results suggest that liver-directed gene therapy has the potential to eradicate inhibitors in dogs. The authors hypothesize that this novel therapy might in the future be used in Hemophilia A patients.
- Third prize: Reinhard Schneppenheim for the research project: A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE
- Von Willebrand Disease (VWD is characterized for a variety of phenotypes that make its classification a complex task. This publication identifies and describes a particular von Willebrand Disease (VWD) phenotype: the VWD type 2A/IIE. The distinct 2A/IIE described here closely resembles classical 2A subtype but lacks a defined triplet structure. These findings will contribute to the understanding of the VWD disease phenotype.
The awards ceremony will be held in October